Editor,
Hereditary proximal spinal muscular atrophy (SMA) is a severe autosomal recessive motor neurone disease caused by survival motor neurone (SMN) protein deficiency due to loss of function of the SMN1 gene. This causes the degeneration of spinal cord alpha-motor neurones leading to muscular weakness. The broad range of SMA severity is captured by the clinical classification system, distinguishing four phenotypes based on age at symptom onset and motor milestone achievement. SMA type 1 is characterised by infantile (<6 months) onset and the inability to sit, type 2 by onset between 6 and 18 months and the inability to walk, and type 3 by onset after 18 months. These patients may lose ambulation before adulthood. Type 4 represents adult-onset SMA.1
Weakness is most pronounced in axial, respiratory and proximal limb muscle groups. Susceptibility to respiratory infections due to a weak cough and need for scoliosis surgery before puberty are common complications in severely affected patients (i.e. SMA types 1 and 2).1 Brainstem motor nuclei are also affected, as reflected by limitations in maximal mouth opening (MMO) due to atrophy and fatty degeneration of the lateral pterygoid muscles, in addition to better known problems with chewing and swallowing. MMO limitations occur in 50 to 100% of patients depending on SMA severity, but patients are often unaware of this complication. Limitations in MMO progress with disease duration.2,3
Endotracheal intubation is a crucial and frequently used procedure in hospital care for SMA patients.1 Limitations in MMO have long been known to complicate this procedure,4,5 although previously it has not been studied specifically for SMA patients. We hypothesised that disease-specific MMO limitations in SMA may complicate intubation procedures as well. Therefore, we retrospectively reviewed all anaesthesiology reports of SMA patients currently participating in our national cohort study who received scoliosis surgery before the age of 18 years between 1991 and 2015 at our tertiary referral centre. We systematically extracted details of intubation procedures, including all comments on procedural complications. Patient characteristics, including SMA type and last documented MMO, defined as the distance between upper and lower front teeth plus overbite, were extracted from the national SMA registry.6 All participants had genetically confirmed SMA. Written informed consent for the use of these data was obtained. Ethical approval for our observational cohort study was obtained from the Medical Ethical Review Committee of the University Medical Centre Utrecht, Utrecht, The Netherlands (Chairperson E.M. van de Putte, MD, PhD) on 18 January 2010 (No. 09-307/NL29692.041.09). Details of all other methods and procedures were published previously.6
We identified 36 patients fulfilling inclusion criteria. Detailed anaesthesiology reports were available from 28 (77%) patients. Mean age at surgery was 8.1 years (median: 7.6 years, range: 3.9 to 15.5 years), mean disease duration 7.4 years (median: 6.7 years, range: 3.3 to 15 years). Five (18%) patients had SMA type 1c (i.e. the mildest variant of the SMA type 1 spectrum1) and 23 (82%) SMA type 2. Important complications of endotracheal intubation, explicitly attributed to MMO limitations, were documented in five (18%) cases (Table 1). These five patients had a mean MMO of 12 mm (median: 14 mm; range: 6 to 18 mm) at time of inclusion in our cohort study (Table 1). MMO data of 20 of the 23 (87%) patients without reported intubation problems was available and significantly larger (U = 17, P = 0.027, r = 0.44) at a mean of 26 mm (median: 26.5 mm; range: 8 to 45 mm). For further context, the range of MMO measurements in 174 patients with SMA participating in our population-based cohort study is summarised in Fig. 1.
Table 1.
Complicated endotracheal intubation in spinal muscular atrophy patients with limited maximal mouth opening
| No. | SMA type | Year of birth | Age at surgery (years) | Year of surgery | Mouth opening in mma | Complications during intubation and procedure-related commentsb |
| 1 | 1c | 1997 | 15.5 | 2012 | 15 | Limited mouth opening necessitated fibre-optic nasal intubation |
| 2 | 1c | 1999 | 5.1 | 2004 | 8 | Nasal intubation was performed, due to very limited mouth opening |
| 3 | 1c | 2002 | 5.3 | 2007 | 18 | Very difficult oral intubation due to limited mouth opening, eventually successful |
| 4 | 2 | 1992 | 9.9 | 2002 | 6 | Fibre-optic oral intubation was performed, because of very limited mouth opening |
| 5 | 2 | 2001 | 4.5 | 2005 | 14 | Difficult oral intubation due to limited mouth opening, even with a glidescope, causing temporary hypoventilation. Afterwards fibre-optic nasal intubation was performed |
MMO, maximal mouth opening; SMA, spinal muscular atrophy. All intubation procedures were performed by paediatric anaesthesiologists and if fibre-optic nasal intubation was necessary, they were assisted by paediatric otorhinolaryngologists.
aMeasured in millimetres.
bAs reported by the anaesthesiologist.
Fig. 1.

(a) Maximal mouth opening measurements in millimetres in spinal muscular atrophy patients with complicated or uncomplicated endotracheal intubation prior to scoliosis surgery. For context, maximal mouth opening measurements in 174 spinal muscular atrophy patients in whom maximal mouth opening was measured as part of our national registry are shown in (b). Dotted horizontal lines represent a maximal mouth opening of 35 mm, the lower limit of a normal maximal mouth opening.2
Limitations in MMO are one of the symptoms in SMA caused by involvement of brainstem motor nuclei. Prevalence figures of reduced MMO, defined as 35 mm or less based on studies in healthy controls, range from 80 to 100% in patients with SMA types 1 and 2, and up to 50% in SMA type 3.2,3 Patients are often unaware of a reduced MMO despite the fact that it may interfere with daily activities such as biting, eating and dental care. Progression rates have not been studied, but previous cohort studies have shown that MMO limitations may occur already in the 1st decade.2
We selected anaesthesiology reports during scoliosis surgery to investigate consequences of limited MMO in patients with SMA for medical care, as scoliosis is an important complication that occurs in all children with SMA types 1, 2 and the majority of 3a and requires surgery early in life.1 Our data suggest that these MMO limitations can severely complicate endotracheal intubation procedures in patients with SMA. This is important to recognise, as MMO limitations are a specific complication in SMA patients, the need for endotracheal intubation procedures is increasing and not limited to planned procedures. Patients with SMA types 1 and 2 are frequently admitted to the ICU because of problems with clearance of secretions during airway tract infections. Under such circumstances, uncomplicated intubation procedures are vital for patient safety.
The available data suggest that the risk of a complicated intubation procedure particularly increases with an MMO of 20 mm or less (Fig. 1). It is important to note that this represents an estimate, as these values were not always obtained at intubation or pre-operative screening but often considerably later at enrolment in our registry. Considering that MMO progressively decreases over time, values above 20 mm may already be associated with complicated intubation procedures in SMA patients. We have previously observed that such severe limitations in MMO are not uncommon in children with SMA under 10 years of age.2
Recent introduction of the first SMA-specific therapy suggests that prognosis of SMA will improve in the coming decade. Limitations of MMO will, however, occur as long as SMA cannot be cured. Improved life expectancy of severe SMA may increase the need for medical treatments and procedures that require intubation.7 Awareness of this SMA-specific complication among paediatricians, intensive care specialists and anaesthesiologists is therefore important, as is the regular assessment of MMO limitations and documentation in patient files.
Acknowledgements relating to this article
Assistance with the study: we thank Esther S. Veldhoen, paediatric critical care specialist from the department of paediatric intensive care (Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht University, The Netherlands) for her helpful comments and contribution to our work. We would also like to thank Louise A.M. Otto, MD; A.M.B. van der Heul, speech-language pathologist; Ton Schouten, paediatric anaesthesiologist; and Willemijn van Bruggen, dentist–gnathologist, for their helpful comments.
Financial support and sponsorship: SMA research at the University Medical Centre of Utrecht has been supported by grants from the ‘Prinses Beatrix Spierfonds’ (WAR08-24, WAR13-07, WAR14-26) and ‘Stichting Spieren voor Spieren’.
Conflicts of interest: WLvdP receives research support from the Prinses Beatrix Spierfonds, Stichting Spieren voor Spieren, The Netherlands ALS foundation. His employer receives fees for consultancy services to Biogen, Avexis (scientific advisory board) and Novartis (data monitoring committee).
References
- 1.Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 2012; 11:443–452. [DOI] [PubMed] [Google Scholar]
- 2.Wadman RI, van Bruggen HW, Witkamp TD, et al. Bulbar muscle MRI changes in patients with SMA with reduced mouth opening and dysphagia. Neurology 2014; 83:1060–1066. [DOI] [PubMed] [Google Scholar]
- 3.van Bruggen HW, Wadman RI, Bronkhorst EM, et al. Mandibular dysfunction as a reflection of bulbar involvement in SMA type 2 and 3. Neurology 2016; 86:552–559. [DOI] [PubMed] [Google Scholar]
- 4.Benumof JL. Management of the difficult adult airway. With special emphasis on awake tracheal intubation. Anesthesiology 1991; 75:1087–1110. [DOI] [PubMed] [Google Scholar]
- 5.Randell T. Prediction of difficult intubation. Acta Anaesthesiol Scand 1996; 40:1016–1023. [DOI] [PubMed] [Google Scholar]
- 6.Wadman RI, Stam M, Gijzen M, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4. J Neurol Neurosurg Psychiatry 2017; 88:365–367. [DOI] [PubMed] [Google Scholar]
- 7.King NMP, Bishop CE. New treatments for serious conditions: ethical implications. Gene Ther 2017; 24:534–538. [DOI] [PubMed] [Google Scholar]
